NASDAQ:ADXN Addex Therapeutics - ADXN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. $1.10 -0.12 (-9.47%) (As of 03/17/2023 08:53 PM ET) Add Compare Share Share Today's Range$1.07▼$1.2150-Day Range$0.70▼$2.1952-Week Range$0.55▼$5.45Volume79,900 shsAverage Volume370,177 shsMarket Capitalization$14.15 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Addex Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,263.6% Upside$15.00 Price TargetShort InterestHealthy2.63% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 starsMedical Sector848th out of 983 stocksPharmaceutical Preparations Industry408th out of 480 stocks 3.0 Analyst's Opinion Consensus RatingAddex Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Addex Therapeutics has a forecasted upside of 1,263.6% from its current price of $1.10.Amount of Analyst CoverageAddex Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.63% of the outstanding shares of Addex Therapeutics have been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Addex Therapeutics has recently increased by 149.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAddex Therapeutics does not currently pay a dividend.Dividend GrowthAddex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADXN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Addex Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 7 people have searched for ADXN on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows1 people have added Addex Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Addex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Addex Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Addex Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAddex Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Addex Therapeutics (NASDAQ:ADXN) StockAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Read More Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXN Stock News HeadlinesMarch 16, 2023 | finance.yahoo.comAddex Announces Upcoming Conferences it will participate for H1 2023March 1, 2023 | seekingalpha.comADXN Addex Therapeutics LtdMarch 20, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 9, 2023 | finanznachrichten.deAddex Therapeutics: Addex Regains Nasdaq Listing ComplianceFebruary 9, 2023 | finance.yahoo.comAddex Regains Nasdaq Listing ComplianceFebruary 6, 2023 | finanznachrichten.deAddex Therapeutics: Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1February 6, 2023 | finance.yahoo.comAddex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1December 8, 2022 | seekingalpha.comAddex rises 10% on extended research pact with Indivior to develop substance use disorder drugsMarch 20, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …December 8, 2022 | finance.yahoo.comAddex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery CollaborationNovember 14, 2022 | seekingalpha.comAddex Therapeutics Ltd (ADXN) Q3 2022 Earnings Call TranscriptNovember 12, 2022 | finanznachrichten.deAddex Therapeutics: Addex Reports Q3 2022 Financial Results and Provides Corporate UpdateNovember 11, 2022 | finance.yahoo.comAddex Reports Q3 2022 Financial Results and Provides Corporate UpdateNovember 10, 2022 | 247wallst.comTim Dyer Ups Take in Addex Therapeutics Ltd (ADXN) to over 20%November 3, 2022 | finance.yahoo.comAddex Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNovember 3, 2022 | finance.yahoo.comAddex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022September 20, 2022 | finance.yahoo.comAddex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment ConferenceAugust 19, 2022 | benzinga.comAddex Reports 2022 Half Year and Second Quarter...August 18, 2022 | finance.yahoo.comAddex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate UpdateAugust 15, 2022 | finance.yahoo.comAddex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use DisordersAugust 12, 2022 | finance.yahoo.comAddex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022July 26, 2022 | finance.yahoo.comAddex Completes $4.2 Million Equity FinancingJuly 22, 2022 | finance.yahoo.comAddex Raises $4.2 million in Equity FinancingJuly 21, 2022 | finance.yahoo.comWhat's Happening With Addex Therapeutics Shares TodayJuly 21, 2022 | finance.yahoo.comAddex Provides Corporate Update and Financial GuidanceJuly 21, 2022 | finance.yahoo.comAddex Completes Reduction in Nominal Value of SharesJune 19, 2022 | uk.investing.comWhy Shares Of Addex Therapeutics Are Falling TodaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXN Company Calendar Last Earnings11/04/2021Today3/20/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADXN CUSIPN/A CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+1,263.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,800,000.00 Net Margins-1,737.41% Pretax Margin-1,737.49% Return on Equity-190.82% Return on Assets-133.87% Debt Debt-to-Equity RatioN/A Current Ratio2.83 Quick Ratio2.83 Sales & Book Value Annual Sales$1.23 million Price / Sales11.52 Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book0.49Miscellaneous Outstanding Shares12,858,000Free Float10,929,000Market Cap$14.14 million OptionableNot Optionable Beta1.89 Key ExecutivesMr. Timothy Mark Dyer (Age 54)Co-Founder, CEO & Director Dr. Roger G. Mills M.D. (Age 65)Chief Medical Officer & Director Mr. Lénaic Teyssédou (Age 36)Head of Fin. Dr. Jean-Philippe Rocher Ph.D. (Age 63)Head of Discovery - Chemistry Dr. Robert Lutjens (Age 54)Head of Discovery - Biology Dr. Mikhail Kalinichev Ph.D. (Age 54)Head of Translational Science Dr. Werner Henrichi Ph.D. (Age 79)Consultant More ExecutivesKey CompetitorsLiminal BioSciencesNASDAQ:LMNLChembio DiagnosticsNASDAQ:CEMIGelesisNYSE:GLSAprea TherapeuticsNASDAQ:APREApplied Molecular TransportNASDAQ:AMTIView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 72,142 shares on 2/14/2023Ownership: 0.561%NEA Management Company LLCSold 4,568,690 shares on 2/10/2023Ownership: 8.398%View All Institutional Transactions ADXN Stock - Frequently Asked Questions Should I buy or sell Addex Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares. View ADXN analyst ratings or view top-rated stocks. What is Addex Therapeutics' stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month target prices for Addex Therapeutics' stock. Their ADXN share price forecasts range from $15.00 to $15.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,263.6% from the stock's current price. View analysts price targets for ADXN or view top-rated stocks among Wall Street analysts. How have ADXN shares performed in 2023? Addex Therapeutics' stock was trading at $0.6301 at the beginning of 2023. Since then, ADXN stock has increased by 74.6% and is now trading at $1.10. View the best growth stocks for 2023 here. Are investors shorting Addex Therapeutics? Addex Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 338,700 shares, an increase of 149.8% from the February 13th total of 135,600 shares. Based on an average daily volume of 304,500 shares, the short-interest ratio is presently 1.1 days. View Addex Therapeutics' Short Interest. When is Addex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our ADXN earnings forecast. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd (NASDAQ:ADXN) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, hitting analysts' consensus estimates of ($0.72). The firm had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.42 million. Addex Therapeutics had a negative net margin of 1,737.41% and a negative trailing twelve-month return on equity of 190.82%. During the same quarter in the previous year, the business posted ($0.78) earnings per share. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced Biomedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). What is Addex Therapeutics' stock symbol? Addex Therapeutics trades on the NASDAQ under the ticker symbol "ADXN." Who are Addex Therapeutics' major shareholders? Addex Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (8.40%) and Susquehanna International Group LLP (0.56%). How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Addex Therapeutics' stock price today? One share of ADXN stock can currently be purchased for approximately $1.10. How much money does Addex Therapeutics make? Addex Therapeutics (NASDAQ:ADXN) has a market capitalization of $14.14 million and generates $1.23 million in revenue each year. The company earns $-16,800,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. How can I contact Addex Therapeutics? Addex Therapeutics' mailing address is CHEMIN DES AULX 12 PLAN-LES-OUATES, GENEVA V8, CH-1228. The official website for the company is www.addextherapeutics.com. The company can be reached via phone at 011-41-22-884-1555, via email at investor.relations@addextherapeutics.com, or via fax at 41-22-884-1556. This page (NASDAQ:ADXN) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.